Global Toripalimab Market Growth 2026-2032
The global Toripalimab market size is predicted to grow from US$ 313 million in 2025 to US$ 890 million in 2032; it is expected to grow at a CAGR of 14.2% from 2026 to 2032.
Toripalimab is a humanized IgG4 monoclonal antibody and a programmed cell death protein-1 (PD-1) immune checkpoint inhibitor. It works by binding to the PD-1 receptor on T cells, thereby blocking its interaction with PD-L1 and PD-L2. This mechanism relieves tumor-induced immunosuppression and restores and enhances the body?s anti-tumor immune response. Toripalimab is primarily used in the immunotherapy of various malignancies, such as melanoma, non-small cell lung cancer (NSCLC), and nasopharyngeal carcinoma. It has significant clinical value in the field of cancer immunotherapy.In 2025, global production of toripalimab reached approximately 1.2 million vials.
Toripalimab, as one of the first domestically developed and successfully internationalized PD-1 immune checkpoint inhibitors in China, holds an important position in the cancer immunotherapy market. With the continuous rise in global cancer incidence and the expanding clinical application of immunotherapy across multiple solid tumors, the PD-1 inhibitor market is maintaining rapid growth. Toripalimab has achieved relatively high market penetration in China, supported by a broad range of approved indications, the advancement of reimbursement coverage, and strong clinical performance in tumor types such as nasopharyngeal carcinoma. It is also gradually expanding into overseas markets, including Europe and the United States. From a competitive landscape perspective, the market is dominated by global blockbuster products such as pembrolizumab and nivolumab. However, domestic products demonstrate certain competitive advantages driven by pricing benefits and policy support. Looking ahead, with the approval of additional indications and the expansion of international commercialization, the market size of toripalimab is expected to continue growing, strengthening its position in the global PD-1 inhibitor landscape.
LP Information, Inc. (LPI) ' newest research report, the ?Toripalimab Industry Forecast? looks at past sales and reviews total world Toripalimab sales in 2025, providing a comprehensive analysis by region and market sector of projected Toripalimab sales for 2026 through 2032. With Toripalimab sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Toripalimab industry.
This Insight Report provides a comprehensive analysis of the global Toripalimab landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Toripalimab portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Toripalimab market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Toripalimab and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Toripalimab.
This report presents a comprehensive overview, market shares, and growth opportunities of Toripalimab market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Toripalimab market?
What factors are driving Toripalimab market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Toripalimab market opportunities vary by end market size?
How does Toripalimab break out by Type, by Application?
Toripalimab is a humanized IgG4 monoclonal antibody and a programmed cell death protein-1 (PD-1) immune checkpoint inhibitor. It works by binding to the PD-1 receptor on T cells, thereby blocking its interaction with PD-L1 and PD-L2. This mechanism relieves tumor-induced immunosuppression and restores and enhances the body?s anti-tumor immune response. Toripalimab is primarily used in the immunotherapy of various malignancies, such as melanoma, non-small cell lung cancer (NSCLC), and nasopharyngeal carcinoma. It has significant clinical value in the field of cancer immunotherapy.In 2025, global production of toripalimab reached approximately 1.2 million vials.
Toripalimab, as one of the first domestically developed and successfully internationalized PD-1 immune checkpoint inhibitors in China, holds an important position in the cancer immunotherapy market. With the continuous rise in global cancer incidence and the expanding clinical application of immunotherapy across multiple solid tumors, the PD-1 inhibitor market is maintaining rapid growth. Toripalimab has achieved relatively high market penetration in China, supported by a broad range of approved indications, the advancement of reimbursement coverage, and strong clinical performance in tumor types such as nasopharyngeal carcinoma. It is also gradually expanding into overseas markets, including Europe and the United States. From a competitive landscape perspective, the market is dominated by global blockbuster products such as pembrolizumab and nivolumab. However, domestic products demonstrate certain competitive advantages driven by pricing benefits and policy support. Looking ahead, with the approval of additional indications and the expansion of international commercialization, the market size of toripalimab is expected to continue growing, strengthening its position in the global PD-1 inhibitor landscape.
LP Information, Inc. (LPI) ' newest research report, the ?Toripalimab Industry Forecast? looks at past sales and reviews total world Toripalimab sales in 2025, providing a comprehensive analysis by region and market sector of projected Toripalimab sales for 2026 through 2032. With Toripalimab sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Toripalimab industry.
This Insight Report provides a comprehensive analysis of the global Toripalimab landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Toripalimab portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Toripalimab market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Toripalimab and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Toripalimab.
This report presents a comprehensive overview, market shares, and growth opportunities of Toripalimab market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Monoclonal Antibody, mAb
- Bispecific Antibody, BsAb
- 80 mg / 4 mL
- 240 mg / 6 mL
- Innovator
- Generic
- Injection
- Sterile Powder for Injection
- Melanoma
- Non-Small Cell Lung Cancer
- Nasopharyngeal Carcinoma, NPC
- Esophageal Cancer
- Hepatocellular Carcinoma, HCC
- Urothelial Carcinoma
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Shanghai Junshi Biosciences
- Coherus BioSciences
- Apotex
What is the 10-year outlook for the global Toripalimab market?
What factors are driving Toripalimab market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Toripalimab market opportunities vary by end market size?
How does Toripalimab break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Toripalimab Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Toripalimab by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Toripalimab by Country/Region, 2021, 2025 & 2032
2.2 Toripalimab Segment by Type
2.2.1 Monoclonal Antibody, mAb
2.2.2 Bispecific Antibody, BsAb
2.2.3 Toripalimab Sales by Type
2.2.3.1 Global Toripalimab Sales Market Share by Type (2021-2026)
2.2.3.2 Global Toripalimab Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Toripalimab Sale Price by Type (2021-2026)
2.3 Toripalimab Segment by Specification
2.3.1 80 mg / 4 mL
2.3.2 240 mg / 6 mL
2.3.3 Toripalimab Sales by Specification
2.3.3.1 Global Toripalimab Sales Market Share by Specification (2021-2026)
2.3.3.2 Global Toripalimab Revenue and Market Share by Specification (2021-2026)
2.3.3.3 Global Toripalimab Sale Price by Specification (2021-2026)
2.4 Toripalimab Segment by Sales Channels
2.4.1 Innovator
2.4.2 Generic
2.4.3 Toripalimab Sales by Sales Channels
2.4.3.1 Global Toripalimab Sales Market Share by Sales Channels (2021-2026)
2.4.3.2 Global Toripalimab Revenue and Market Share by Sales Channels (2021-2026)
2.4.3.3 Global Toripalimab Sale Price by Sales Channels (2021-2026)
2.5 Toripalimab Segment by Dosage Form
2.5.1 Injection
2.5.2 Sterile Powder for Injection
2.5.3 Toripalimab Sales by Dosage Form
2.5.3.1 Global Toripalimab Sales Market Share by Dosage Form (2021-2026)
2.5.3.2 Global Toripalimab Revenue and Market Share by Dosage Form (2021-2026)
2.5.3.3 Global Toripalimab Sale Price by Dosage Form (2021-2026)
2.6 Toripalimab Segment by Application
2.6.1 Melanoma
2.6.2 Non-Small Cell Lung Cancer
2.6.3 Nasopharyngeal Carcinoma, NPC
2.6.4 Esophageal Cancer
2.6.5 Hepatocellular Carcinoma, HCC
2.6.6 Urothelial Carcinoma
2.6.7 Others
2.6.8 Toripalimab Sales by Application
2.6.8.1 Global Toripalimab Sale Market Share by Application (2021-2026)
2.6.8.2 Global Toripalimab Revenue and Market Share by Application (2021-2026)
2.6.8.3 Global Toripalimab Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Toripalimab Breakdown Data by Company
3.1.1 Global Toripalimab Annual Sales by Company (2021-2026)
3.1.2 Global Toripalimab Sales Market Share by Company (2021-2026)
3.2 Global Toripalimab Annual Revenue by Company (2021-2026)
3.2.1 Global Toripalimab Revenue by Company (2021-2026)
3.2.2 Global Toripalimab Revenue Market Share by Company (2021-2026)
3.3 Global Toripalimab Sale Price by Company
3.4 Key Manufacturers Toripalimab Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Toripalimab Product Location Distribution
3.4.2 Players Toripalimab Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR TORIPALIMAB BY GEOGRAPHIC REGION
4.1 World Historic Toripalimab Market Size by Geographic Region (2021-2026)
4.1.1 Global Toripalimab Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Toripalimab Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Toripalimab Market Size by Country/Region (2021-2026)
4.2.1 Global Toripalimab Annual Sales by Country/Region (2021-2026)
4.2.2 Global Toripalimab Annual Revenue by Country/Region (2021-2026)
4.3 Americas Toripalimab Sales Growth
4.4 APAC Toripalimab Sales Growth
4.5 Europe Toripalimab Sales Growth
4.6 Middle East & Africa Toripalimab Sales Growth
5 AMERICAS
5.1 Americas Toripalimab Sales by Country
5.1.1 Americas Toripalimab Sales by Country (2021-2026)
5.1.2 Americas Toripalimab Revenue by Country (2021-2026)
5.2 Americas Toripalimab Sales by Type (2021-2026)
5.3 Americas Toripalimab Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Toripalimab Sales by Region
6.1.1 APAC Toripalimab Sales by Region (2021-2026)
6.1.2 APAC Toripalimab Revenue by Region (2021-2026)
6.2 APAC Toripalimab Sales by Type (2021-2026)
6.3 APAC Toripalimab Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Toripalimab by Country
7.1.1 Europe Toripalimab Sales by Country (2021-2026)
7.1.2 Europe Toripalimab Revenue by Country (2021-2026)
7.2 Europe Toripalimab Sales by Type (2021-2026)
7.3 Europe Toripalimab Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Toripalimab by Country
8.1.1 Middle East & Africa Toripalimab Sales by Country (2021-2026)
8.1.2 Middle East & Africa Toripalimab Revenue by Country (2021-2026)
8.2 Middle East & Africa Toripalimab Sales by Type (2021-2026)
8.3 Middle East & Africa Toripalimab Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Toripalimab
10.3 Manufacturing Process Analysis of Toripalimab
10.4 Industry Chain Structure of Toripalimab
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Toripalimab Distributors
11.3 Toripalimab Customer
12 WORLD FORECAST REVIEW FOR TORIPALIMAB BY GEOGRAPHIC REGION
12.1 Global Toripalimab Market Size Forecast by Region
12.1.1 Global Toripalimab Forecast by Region (2027-2032)
12.1.2 Global Toripalimab Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Toripalimab Forecast by Type (2027-2032)
12.7 Global Toripalimab Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Shanghai Junshi Biosciences
13.1.1 Shanghai Junshi Biosciences Company Information
13.1.2 Shanghai Junshi Biosciences Toripalimab Product Portfolios and Specifications
13.1.3 Shanghai Junshi Biosciences Toripalimab Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Shanghai Junshi Biosciences Main Business Overview
13.1.5 Shanghai Junshi Biosciences Latest Developments
13.2 Coherus BioSciences
13.2.1 Coherus BioSciences Company Information
13.2.2 Coherus BioSciences Toripalimab Product Portfolios and Specifications
13.2.3 Coherus BioSciences Toripalimab Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Coherus BioSciences Main Business Overview
13.2.5 Coherus BioSciences Latest Developments
13.3 Apotex
13.3.1 Apotex Company Information
13.3.2 Apotex Toripalimab Product Portfolios and Specifications
13.3.3 Apotex Toripalimab Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Apotex Main Business Overview
13.3.5 Apotex Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Toripalimab Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Toripalimab by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Toripalimab by Country/Region, 2021, 2025 & 2032
2.2 Toripalimab Segment by Type
2.2.1 Monoclonal Antibody, mAb
2.2.2 Bispecific Antibody, BsAb
2.2.3 Toripalimab Sales by Type
2.2.3.1 Global Toripalimab Sales Market Share by Type (2021-2026)
2.2.3.2 Global Toripalimab Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Toripalimab Sale Price by Type (2021-2026)
2.3 Toripalimab Segment by Specification
2.3.1 80 mg / 4 mL
2.3.2 240 mg / 6 mL
2.3.3 Toripalimab Sales by Specification
2.3.3.1 Global Toripalimab Sales Market Share by Specification (2021-2026)
2.3.3.2 Global Toripalimab Revenue and Market Share by Specification (2021-2026)
2.3.3.3 Global Toripalimab Sale Price by Specification (2021-2026)
2.4 Toripalimab Segment by Sales Channels
2.4.1 Innovator
2.4.2 Generic
2.4.3 Toripalimab Sales by Sales Channels
2.4.3.1 Global Toripalimab Sales Market Share by Sales Channels (2021-2026)
2.4.3.2 Global Toripalimab Revenue and Market Share by Sales Channels (2021-2026)
2.4.3.3 Global Toripalimab Sale Price by Sales Channels (2021-2026)
2.5 Toripalimab Segment by Dosage Form
2.5.1 Injection
2.5.2 Sterile Powder for Injection
2.5.3 Toripalimab Sales by Dosage Form
2.5.3.1 Global Toripalimab Sales Market Share by Dosage Form (2021-2026)
2.5.3.2 Global Toripalimab Revenue and Market Share by Dosage Form (2021-2026)
2.5.3.3 Global Toripalimab Sale Price by Dosage Form (2021-2026)
2.6 Toripalimab Segment by Application
2.6.1 Melanoma
2.6.2 Non-Small Cell Lung Cancer
2.6.3 Nasopharyngeal Carcinoma, NPC
2.6.4 Esophageal Cancer
2.6.5 Hepatocellular Carcinoma, HCC
2.6.6 Urothelial Carcinoma
2.6.7 Others
2.6.8 Toripalimab Sales by Application
2.6.8.1 Global Toripalimab Sale Market Share by Application (2021-2026)
2.6.8.2 Global Toripalimab Revenue and Market Share by Application (2021-2026)
2.6.8.3 Global Toripalimab Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Toripalimab Breakdown Data by Company
3.1.1 Global Toripalimab Annual Sales by Company (2021-2026)
3.1.2 Global Toripalimab Sales Market Share by Company (2021-2026)
3.2 Global Toripalimab Annual Revenue by Company (2021-2026)
3.2.1 Global Toripalimab Revenue by Company (2021-2026)
3.2.2 Global Toripalimab Revenue Market Share by Company (2021-2026)
3.3 Global Toripalimab Sale Price by Company
3.4 Key Manufacturers Toripalimab Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Toripalimab Product Location Distribution
3.4.2 Players Toripalimab Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR TORIPALIMAB BY GEOGRAPHIC REGION
4.1 World Historic Toripalimab Market Size by Geographic Region (2021-2026)
4.1.1 Global Toripalimab Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Toripalimab Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Toripalimab Market Size by Country/Region (2021-2026)
4.2.1 Global Toripalimab Annual Sales by Country/Region (2021-2026)
4.2.2 Global Toripalimab Annual Revenue by Country/Region (2021-2026)
4.3 Americas Toripalimab Sales Growth
4.4 APAC Toripalimab Sales Growth
4.5 Europe Toripalimab Sales Growth
4.6 Middle East & Africa Toripalimab Sales Growth
5 AMERICAS
5.1 Americas Toripalimab Sales by Country
5.1.1 Americas Toripalimab Sales by Country (2021-2026)
5.1.2 Americas Toripalimab Revenue by Country (2021-2026)
5.2 Americas Toripalimab Sales by Type (2021-2026)
5.3 Americas Toripalimab Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Toripalimab Sales by Region
6.1.1 APAC Toripalimab Sales by Region (2021-2026)
6.1.2 APAC Toripalimab Revenue by Region (2021-2026)
6.2 APAC Toripalimab Sales by Type (2021-2026)
6.3 APAC Toripalimab Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Toripalimab by Country
7.1.1 Europe Toripalimab Sales by Country (2021-2026)
7.1.2 Europe Toripalimab Revenue by Country (2021-2026)
7.2 Europe Toripalimab Sales by Type (2021-2026)
7.3 Europe Toripalimab Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Toripalimab by Country
8.1.1 Middle East & Africa Toripalimab Sales by Country (2021-2026)
8.1.2 Middle East & Africa Toripalimab Revenue by Country (2021-2026)
8.2 Middle East & Africa Toripalimab Sales by Type (2021-2026)
8.3 Middle East & Africa Toripalimab Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Toripalimab
10.3 Manufacturing Process Analysis of Toripalimab
10.4 Industry Chain Structure of Toripalimab
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Toripalimab Distributors
11.3 Toripalimab Customer
12 WORLD FORECAST REVIEW FOR TORIPALIMAB BY GEOGRAPHIC REGION
12.1 Global Toripalimab Market Size Forecast by Region
12.1.1 Global Toripalimab Forecast by Region (2027-2032)
12.1.2 Global Toripalimab Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Toripalimab Forecast by Type (2027-2032)
12.7 Global Toripalimab Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Shanghai Junshi Biosciences
13.1.1 Shanghai Junshi Biosciences Company Information
13.1.2 Shanghai Junshi Biosciences Toripalimab Product Portfolios and Specifications
13.1.3 Shanghai Junshi Biosciences Toripalimab Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Shanghai Junshi Biosciences Main Business Overview
13.1.5 Shanghai Junshi Biosciences Latest Developments
13.2 Coherus BioSciences
13.2.1 Coherus BioSciences Company Information
13.2.2 Coherus BioSciences Toripalimab Product Portfolios and Specifications
13.2.3 Coherus BioSciences Toripalimab Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Coherus BioSciences Main Business Overview
13.2.5 Coherus BioSciences Latest Developments
13.3 Apotex
13.3.1 Apotex Company Information
13.3.2 Apotex Toripalimab Product Portfolios and Specifications
13.3.3 Apotex Toripalimab Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Apotex Main Business Overview
13.3.5 Apotex Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Toripalimab Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Toripalimab Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Monoclonal Antibody, mAb
Table 4. Major Players of Bispecific Antibody, BsAb
Table 5. Global Toripalimab Sales by Type (2021-2026) & (Units)
Table 6. Global Toripalimab Sales Market Share by Type (2021-2026)
Table 7. Global Toripalimab Revenue by Type (2021-2026) & ($ million)
Table 8. Global Toripalimab Revenue Market Share by Type (2021-2026)
Table 9. Global Toripalimab Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of 80 mg / 4 mL
Table 11. Major Players of 240 mg / 6 mL
Table 12. Global Toripalimab Sales by Specification (2021-2026) & (Units)
Table 13. Global Toripalimab Sales Market Share by Specification (2021-2026)
Table 14. Global Toripalimab Revenue by Specification (2021-2026) & ($ million)
Table 15. Global Toripalimab Revenue Market Share by Specification (2021-2026)
Table 16. Global Toripalimab Sale Price by Specification (2021-2026) & (US$/Unit)
Table 17. Major Players of Innovator
Table 18. Major Players of Generic
Table 19. Global Toripalimab Sales by Sales Channels (2021-2026) & (Units)
Table 20. Global Toripalimab Sales Market Share by Sales Channels (2021-2026)
Table 21. Global Toripalimab Revenue by Sales Channels (2021-2026) & ($ million)
Table 22. Global Toripalimab Revenue Market Share by Sales Channels (2021-2026)
Table 23. Global Toripalimab Sale Price by Sales Channels (2021-2026) & (US$/Unit)
Table 24. Major Players of Injection
Table 25. Major Players of Sterile Powder for Injection
Table 26. Global Toripalimab Sales by Dosage Form (2021-2026) & (Units)
Table 27. Global Toripalimab Sales Market Share by Dosage Form (2021-2026)
Table 28. Global Toripalimab Revenue by Dosage Form (2021-2026) & ($ million)
Table 29. Global Toripalimab Revenue Market Share by Dosage Form (2021-2026)
Table 30. Global Toripalimab Sale Price by Dosage Form (2021-2026) & (US$/Unit)
Table 31. Global Toripalimab Sale by Application (2021-2026) & (Units)
Table 32. Global Toripalimab Sale Market Share by Application (2021-2026)
Table 33. Global Toripalimab Revenue by Application (2021-2026) & ($ million)
Table 34. Global Toripalimab Revenue Market Share by Application (2021-2026)
Table 35. Global Toripalimab Sale Price by Application (2021-2026) & (US$/Unit)
Table 36. Global Toripalimab Sales by Company (2021-2026) & (Units)
Table 37. Global Toripalimab Sales Market Share by Company (2021-2026)
Table 38. Global Toripalimab Revenue by Company (2021-2026) & ($ millions)
Table 39. Global Toripalimab Revenue Market Share by Company (2021-2026)
Table 40. Global Toripalimab Sale Price by Company (2021-2026) & (US$/Unit)
Table 41. Key Manufacturers Toripalimab Producing Area Distribution and Sales Area
Table 42. Players Toripalimab Products Offered
Table 43. Toripalimab Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 44. New Products and Potential Entrants
Table 45. Market M&A Activity & Strategy
Table 46. Global Toripalimab Sales by Geographic Region (2021-2026) & (Units)
Table 47. Global Toripalimab Sales Market Share Geographic Region (2021-2026)
Table 48. Global Toripalimab Revenue by Geographic Region (2021-2026) & ($ millions)
Table 49. Global Toripalimab Revenue Market Share by Geographic Region (2021-2026)
Table 50. Global Toripalimab Sales by Country/Region (2021-2026) & (Units)
Table 51. Global Toripalimab Sales Market Share by Country/Region (2021-2026)
Table 52. Global Toripalimab Revenue by Country/Region (2021-2026) & ($ millions)
Table 53. Global Toripalimab Revenue Market Share by Country/Region (2021-2026)
Table 54. Americas Toripalimab Sales by Country (2021-2026) & (Units)
Table 55. Americas Toripalimab Sales Market Share by Country (2021-2026)
Table 56. Americas Toripalimab Revenue by Country (2021-2026) & ($ millions)
Table 57. Americas Toripalimab Sales by Type (2021-2026) & (Units)
Table 58. Americas Toripalimab Sales by Application (2021-2026) & (Units)
Table 59. APAC Toripalimab Sales by Region (2021-2026) & (Units)
Table 60. APAC Toripalimab Sales Market Share by Region (2021-2026)
Table 61. APAC Toripalimab Revenue by Region (2021-2026) & ($ millions)
Table 62. APAC Toripalimab Sales by Type (2021-2026) & (Units)
Table 63. APAC Toripalimab Sales by Application (2021-2026) & (Units)
Table 64. Europe Toripalimab Sales by Country (2021-2026) & (Units)
Table 65. Europe Toripalimab Revenue by Country (2021-2026) & ($ millions)
Table 66. Europe Toripalimab Sales by Type (2021-2026) & (Units)
Table 67. Europe Toripalimab Sales by Application (2021-2026) & (Units)
Table 68. Middle East & Africa Toripalimab Sales by Country (2021-2026) & (Units)
Table 69. Middle East & Africa Toripalimab Revenue Market Share by Country (2021-2026)
Table 70. Middle East & Africa Toripalimab Sales by Type (2021-2026) & (Units)
Table 71. Middle East & Africa Toripalimab Sales by Application (2021-2026) & (Units)
Table 72. Key Market Drivers & Growth Opportunities of Toripalimab
Table 73. Key Market Challenges & Risks of Toripalimab
Table 74. Key Industry Trends of Toripalimab
Table 75. Toripalimab Raw Material
Table 76. Key Suppliers of Raw Materials
Table 77. Toripalimab Distributors List
Table 78. Toripalimab Customer List
Table 79. Global Toripalimab Sales Forecast by Region (2027-2032) & (Units)
Table 80. Global Toripalimab Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Americas Toripalimab Sales Forecast by Country (2027-2032) & (Units)
Table 82. Americas Toripalimab Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. APAC Toripalimab Sales Forecast by Region (2027-2032) & (Units)
Table 84. APAC Toripalimab Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 85. Europe Toripalimab Sales Forecast by Country (2027-2032) & (Units)
Table 86. Europe Toripalimab Revenue Forecast by Country (2027-2032) & ($ millions)
Table 87. Middle East & Africa Toripalimab Sales Forecast by Country (2027-2032) & (Units)
Table 88. Middle East & Africa Toripalimab Revenue Forecast by Country (2027-2032) & ($ millions)
Table 89. Global Toripalimab Sales Forecast by Type (2027-2032) & (Units)
Table 90. Global Toripalimab Revenue Forecast by Type (2027-2032) & ($ millions)
Table 91. Global Toripalimab Sales Forecast by Application (2027-2032) & (Units)
Table 92. Global Toripalimab Revenue Forecast by Application (2027-2032) & ($ millions)
Table 93. Shanghai Junshi Biosciences Basic Information, Toripalimab Manufacturing Base, Sales Area and Its Competitors
Table 94. Shanghai Junshi Biosciences Toripalimab Product Portfolios and Specifications
Table 95. Shanghai Junshi Biosciences Toripalimab Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Shanghai Junshi Biosciences Main Business
Table 97. Shanghai Junshi Biosciences Latest Developments
Table 98. Coherus BioSciences Basic Information, Toripalimab Manufacturing Base, Sales Area and Its Competitors
Table 99. Coherus BioSciences Toripalimab Product Portfolios and Specifications
Table 100. Coherus BioSciences Toripalimab Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Coherus BioSciences Main Business
Table 102. Coherus BioSciences Latest Developments
Table 103. Apotex Basic Information, Toripalimab Manufacturing Base, Sales Area and Its Competitors
Table 104. Apotex Toripalimab Product Portfolios and Specifications
Table 105. Apotex Toripalimab Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Apotex Main Business
Table 107. Apotex Latest Developments
Table 1. Toripalimab Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Toripalimab Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Monoclonal Antibody, mAb
Table 4. Major Players of Bispecific Antibody, BsAb
Table 5. Global Toripalimab Sales by Type (2021-2026) & (Units)
Table 6. Global Toripalimab Sales Market Share by Type (2021-2026)
Table 7. Global Toripalimab Revenue by Type (2021-2026) & ($ million)
Table 8. Global Toripalimab Revenue Market Share by Type (2021-2026)
Table 9. Global Toripalimab Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of 80 mg / 4 mL
Table 11. Major Players of 240 mg / 6 mL
Table 12. Global Toripalimab Sales by Specification (2021-2026) & (Units)
Table 13. Global Toripalimab Sales Market Share by Specification (2021-2026)
Table 14. Global Toripalimab Revenue by Specification (2021-2026) & ($ million)
Table 15. Global Toripalimab Revenue Market Share by Specification (2021-2026)
Table 16. Global Toripalimab Sale Price by Specification (2021-2026) & (US$/Unit)
Table 17. Major Players of Innovator
Table 18. Major Players of Generic
Table 19. Global Toripalimab Sales by Sales Channels (2021-2026) & (Units)
Table 20. Global Toripalimab Sales Market Share by Sales Channels (2021-2026)
Table 21. Global Toripalimab Revenue by Sales Channels (2021-2026) & ($ million)
Table 22. Global Toripalimab Revenue Market Share by Sales Channels (2021-2026)
Table 23. Global Toripalimab Sale Price by Sales Channels (2021-2026) & (US$/Unit)
Table 24. Major Players of Injection
Table 25. Major Players of Sterile Powder for Injection
Table 26. Global Toripalimab Sales by Dosage Form (2021-2026) & (Units)
Table 27. Global Toripalimab Sales Market Share by Dosage Form (2021-2026)
Table 28. Global Toripalimab Revenue by Dosage Form (2021-2026) & ($ million)
Table 29. Global Toripalimab Revenue Market Share by Dosage Form (2021-2026)
Table 30. Global Toripalimab Sale Price by Dosage Form (2021-2026) & (US$/Unit)
Table 31. Global Toripalimab Sale by Application (2021-2026) & (Units)
Table 32. Global Toripalimab Sale Market Share by Application (2021-2026)
Table 33. Global Toripalimab Revenue by Application (2021-2026) & ($ million)
Table 34. Global Toripalimab Revenue Market Share by Application (2021-2026)
Table 35. Global Toripalimab Sale Price by Application (2021-2026) & (US$/Unit)
Table 36. Global Toripalimab Sales by Company (2021-2026) & (Units)
Table 37. Global Toripalimab Sales Market Share by Company (2021-2026)
Table 38. Global Toripalimab Revenue by Company (2021-2026) & ($ millions)
Table 39. Global Toripalimab Revenue Market Share by Company (2021-2026)
Table 40. Global Toripalimab Sale Price by Company (2021-2026) & (US$/Unit)
Table 41. Key Manufacturers Toripalimab Producing Area Distribution and Sales Area
Table 42. Players Toripalimab Products Offered
Table 43. Toripalimab Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 44. New Products and Potential Entrants
Table 45. Market M&A Activity & Strategy
Table 46. Global Toripalimab Sales by Geographic Region (2021-2026) & (Units)
Table 47. Global Toripalimab Sales Market Share Geographic Region (2021-2026)
Table 48. Global Toripalimab Revenue by Geographic Region (2021-2026) & ($ millions)
Table 49. Global Toripalimab Revenue Market Share by Geographic Region (2021-2026)
Table 50. Global Toripalimab Sales by Country/Region (2021-2026) & (Units)
Table 51. Global Toripalimab Sales Market Share by Country/Region (2021-2026)
Table 52. Global Toripalimab Revenue by Country/Region (2021-2026) & ($ millions)
Table 53. Global Toripalimab Revenue Market Share by Country/Region (2021-2026)
Table 54. Americas Toripalimab Sales by Country (2021-2026) & (Units)
Table 55. Americas Toripalimab Sales Market Share by Country (2021-2026)
Table 56. Americas Toripalimab Revenue by Country (2021-2026) & ($ millions)
Table 57. Americas Toripalimab Sales by Type (2021-2026) & (Units)
Table 58. Americas Toripalimab Sales by Application (2021-2026) & (Units)
Table 59. APAC Toripalimab Sales by Region (2021-2026) & (Units)
Table 60. APAC Toripalimab Sales Market Share by Region (2021-2026)
Table 61. APAC Toripalimab Revenue by Region (2021-2026) & ($ millions)
Table 62. APAC Toripalimab Sales by Type (2021-2026) & (Units)
Table 63. APAC Toripalimab Sales by Application (2021-2026) & (Units)
Table 64. Europe Toripalimab Sales by Country (2021-2026) & (Units)
Table 65. Europe Toripalimab Revenue by Country (2021-2026) & ($ millions)
Table 66. Europe Toripalimab Sales by Type (2021-2026) & (Units)
Table 67. Europe Toripalimab Sales by Application (2021-2026) & (Units)
Table 68. Middle East & Africa Toripalimab Sales by Country (2021-2026) & (Units)
Table 69. Middle East & Africa Toripalimab Revenue Market Share by Country (2021-2026)
Table 70. Middle East & Africa Toripalimab Sales by Type (2021-2026) & (Units)
Table 71. Middle East & Africa Toripalimab Sales by Application (2021-2026) & (Units)
Table 72. Key Market Drivers & Growth Opportunities of Toripalimab
Table 73. Key Market Challenges & Risks of Toripalimab
Table 74. Key Industry Trends of Toripalimab
Table 75. Toripalimab Raw Material
Table 76. Key Suppliers of Raw Materials
Table 77. Toripalimab Distributors List
Table 78. Toripalimab Customer List
Table 79. Global Toripalimab Sales Forecast by Region (2027-2032) & (Units)
Table 80. Global Toripalimab Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Americas Toripalimab Sales Forecast by Country (2027-2032) & (Units)
Table 82. Americas Toripalimab Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. APAC Toripalimab Sales Forecast by Region (2027-2032) & (Units)
Table 84. APAC Toripalimab Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 85. Europe Toripalimab Sales Forecast by Country (2027-2032) & (Units)
Table 86. Europe Toripalimab Revenue Forecast by Country (2027-2032) & ($ millions)
Table 87. Middle East & Africa Toripalimab Sales Forecast by Country (2027-2032) & (Units)
Table 88. Middle East & Africa Toripalimab Revenue Forecast by Country (2027-2032) & ($ millions)
Table 89. Global Toripalimab Sales Forecast by Type (2027-2032) & (Units)
Table 90. Global Toripalimab Revenue Forecast by Type (2027-2032) & ($ millions)
Table 91. Global Toripalimab Sales Forecast by Application (2027-2032) & (Units)
Table 92. Global Toripalimab Revenue Forecast by Application (2027-2032) & ($ millions)
Table 93. Shanghai Junshi Biosciences Basic Information, Toripalimab Manufacturing Base, Sales Area and Its Competitors
Table 94. Shanghai Junshi Biosciences Toripalimab Product Portfolios and Specifications
Table 95. Shanghai Junshi Biosciences Toripalimab Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Shanghai Junshi Biosciences Main Business
Table 97. Shanghai Junshi Biosciences Latest Developments
Table 98. Coherus BioSciences Basic Information, Toripalimab Manufacturing Base, Sales Area and Its Competitors
Table 99. Coherus BioSciences Toripalimab Product Portfolios and Specifications
Table 100. Coherus BioSciences Toripalimab Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Coherus BioSciences Main Business
Table 102. Coherus BioSciences Latest Developments
Table 103. Apotex Basic Information, Toripalimab Manufacturing Base, Sales Area and Its Competitors
Table 104. Apotex Toripalimab Product Portfolios and Specifications
Table 105. Apotex Toripalimab Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Apotex Main Business
Table 107. Apotex Latest Developments
LIST OF FIGURES
Figure 1. Picture of Toripalimab
Figure 2. Toripalimab Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Toripalimab Sales Growth Rate 2021-2032 (Units)
Figure 7. Global Toripalimab Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Toripalimab Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Toripalimab Sales Market Share by Country/Region (2025)
Figure 10. Toripalimab Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Monoclonal Antibody, mAb
Figure 12. Product Picture of Bispecific Antibody, BsAb
Figure 13. Global Toripalimab Sales Market Share by Type in 2026
Figure 14. Global Toripalimab Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of 80 mg / 4 mL
Figure 16. Product Picture of 240 mg / 6 mL
Figure 17. Global Toripalimab Sales Market Share by Specification in 2026
Figure 18. Global Toripalimab Revenue Market Share by Specification (2021-2026)
Figure 19. Product Picture of Innovator
Figure 20. Product Picture of Generic
Figure 21. Global Toripalimab Sales Market Share by Sales Channels in 2026
Figure 22. Global Toripalimab Revenue Market Share by Sales Channels (2021-2026)
Figure 23. Product Picture of Injection
Figure 24. Product Picture of Sterile Powder for Injection
Figure 25. Global Toripalimab Sales Market Share by Dosage Form in 2026
Figure 26. Global Toripalimab Revenue Market Share by Dosage Form (2021-2026)
Figure 27. Toripalimab Consumed in Melanoma
Figure 28. Global Toripalimab Market: Melanoma (2021-2026) & (Units)
Figure 29. Toripalimab Consumed in Non-Small Cell Lung Cancer
Figure 30. Global Toripalimab Market: Non-Small Cell Lung Cancer (2021-2026) & (Units)
Figure 31. Toripalimab Consumed in Nasopharyngeal Carcinoma, NPC
Figure 32. Global Toripalimab Market: Nasopharyngeal Carcinoma, NPC (2021-2026) & (Units)
Figure 33. Toripalimab Consumed in Esophageal Cancer
Figure 34. Global Toripalimab Market: Esophageal Cancer (2021-2026) & (Units)
Figure 35. Toripalimab Consumed in Hepatocellular Carcinoma, HCC
Figure 36. Global Toripalimab Market: Hepatocellular Carcinoma, HCC (2021-2026) & (Units)
Figure 37. Toripalimab Consumed in Urothelial Carcinoma
Figure 38. Global Toripalimab Market: Urothelial Carcinoma (2021-2026) & (Units)
Figure 39. Toripalimab Consumed in Others
Figure 40. Global Toripalimab Market: Others (2021-2026) & (Units)
Figure 41. Global Toripalimab Sale Market Share by Application (2025)
Figure 42. Global Toripalimab Revenue Market Share by Application in 2025
Figure 43. Toripalimab Sales by Company in 2025 (Units)
Figure 44. Global Toripalimab Sales Market Share by Company in 2025
Figure 45. Toripalimab Revenue by Company in 2025 ($ millions)
Figure 46. Global Toripalimab Revenue Market Share by Company in 2025
Figure 47. Global Toripalimab Sales Market Share by Geographic Region (2021-2026)
Figure 48. Global Toripalimab Revenue Market Share by Geographic Region in 2025
Figure 49. Americas Toripalimab Sales 2021-2026 (Units)
Figure 50. Americas Toripalimab Revenue 2021-2026 ($ millions)
Figure 51. APAC Toripalimab Sales 2021-2026 (Units)
Figure 52. APAC Toripalimab Revenue 2021-2026 ($ millions)
Figure 53. Europe Toripalimab Sales 2021-2026 (Units)
Figure 54. Europe Toripalimab Revenue 2021-2026 ($ millions)
Figure 55. Middle East & Africa Toripalimab Sales 2021-2026 (Units)
Figure 56. Middle East & Africa Toripalimab Revenue 2021-2026 ($ millions)
Figure 57. Americas Toripalimab Sales Market Share by Country in 2025
Figure 58. Americas Toripalimab Revenue Market Share by Country (2021-2026)
Figure 59. Americas Toripalimab Sales Market Share by Type (2021-2026)
Figure 60. Americas Toripalimab Sales Market Share by Application (2021-2026)
Figure 61. United States Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 62. Canada Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 63. Mexico Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 64. Brazil Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 65. APAC Toripalimab Sales Market Share by Region in 2025
Figure 66. APAC Toripalimab Revenue Market Share by Region (2021-2026)
Figure 67. APAC Toripalimab Sales Market Share by Type (2021-2026)
Figure 68. APAC Toripalimab Sales Market Share by Application (2021-2026)
Figure 69. China Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 70. Japan Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 71. South Korea Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 72. Southeast Asia Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 73. India Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 74. Australia Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 75. China Taiwan Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 76. Europe Toripalimab Sales Market Share by Country in 2025
Figure 77. Europe Toripalimab Revenue Market Share by Country (2021-2026)
Figure 78. Europe Toripalimab Sales Market Share by Type (2021-2026)
Figure 79. Europe Toripalimab Sales Market Share by Application (2021-2026)
Figure 80. Germany Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 81. France Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 82. UK Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 83. Italy Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 84. Russia Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 85. Middle East & Africa Toripalimab Sales Market Share by Country (2021-2026)
Figure 86. Middle East & Africa Toripalimab Sales Market Share by Type (2021-2026)
Figure 87. Middle East & Africa Toripalimab Sales Market Share by Application (2021-2026)
Figure 88. Egypt Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 89. South Africa Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 90. Israel Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 91. Turkey Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 92. GCC Countries Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 93. Manufacturing Cost Structure Analysis of Toripalimab in 2026
Figure 94. Manufacturing Process Analysis of Toripalimab
Figure 95. Industry Chain Structure of Toripalimab
Figure 96. Channels of Distribution
Figure 97. Global Toripalimab Sales Market Forecast by Region (2027-2032)
Figure 98. Global Toripalimab Revenue Market Share Forecast by Region (2027-2032)
Figure 99. Global Toripalimab Sales Market Share Forecast by Type (2027-2032)
Figure 100. Global Toripalimab Revenue Market Share Forecast by Type (2027-2032)
Figure 101. Global Toripalimab Sales Market Share Forecast by Application (2027-2032)
Figure 102. Global Toripalimab Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Toripalimab
Figure 2. Toripalimab Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Toripalimab Sales Growth Rate 2021-2032 (Units)
Figure 7. Global Toripalimab Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Toripalimab Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Toripalimab Sales Market Share by Country/Region (2025)
Figure 10. Toripalimab Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Monoclonal Antibody, mAb
Figure 12. Product Picture of Bispecific Antibody, BsAb
Figure 13. Global Toripalimab Sales Market Share by Type in 2026
Figure 14. Global Toripalimab Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of 80 mg / 4 mL
Figure 16. Product Picture of 240 mg / 6 mL
Figure 17. Global Toripalimab Sales Market Share by Specification in 2026
Figure 18. Global Toripalimab Revenue Market Share by Specification (2021-2026)
Figure 19. Product Picture of Innovator
Figure 20. Product Picture of Generic
Figure 21. Global Toripalimab Sales Market Share by Sales Channels in 2026
Figure 22. Global Toripalimab Revenue Market Share by Sales Channels (2021-2026)
Figure 23. Product Picture of Injection
Figure 24. Product Picture of Sterile Powder for Injection
Figure 25. Global Toripalimab Sales Market Share by Dosage Form in 2026
Figure 26. Global Toripalimab Revenue Market Share by Dosage Form (2021-2026)
Figure 27. Toripalimab Consumed in Melanoma
Figure 28. Global Toripalimab Market: Melanoma (2021-2026) & (Units)
Figure 29. Toripalimab Consumed in Non-Small Cell Lung Cancer
Figure 30. Global Toripalimab Market: Non-Small Cell Lung Cancer (2021-2026) & (Units)
Figure 31. Toripalimab Consumed in Nasopharyngeal Carcinoma, NPC
Figure 32. Global Toripalimab Market: Nasopharyngeal Carcinoma, NPC (2021-2026) & (Units)
Figure 33. Toripalimab Consumed in Esophageal Cancer
Figure 34. Global Toripalimab Market: Esophageal Cancer (2021-2026) & (Units)
Figure 35. Toripalimab Consumed in Hepatocellular Carcinoma, HCC
Figure 36. Global Toripalimab Market: Hepatocellular Carcinoma, HCC (2021-2026) & (Units)
Figure 37. Toripalimab Consumed in Urothelial Carcinoma
Figure 38. Global Toripalimab Market: Urothelial Carcinoma (2021-2026) & (Units)
Figure 39. Toripalimab Consumed in Others
Figure 40. Global Toripalimab Market: Others (2021-2026) & (Units)
Figure 41. Global Toripalimab Sale Market Share by Application (2025)
Figure 42. Global Toripalimab Revenue Market Share by Application in 2025
Figure 43. Toripalimab Sales by Company in 2025 (Units)
Figure 44. Global Toripalimab Sales Market Share by Company in 2025
Figure 45. Toripalimab Revenue by Company in 2025 ($ millions)
Figure 46. Global Toripalimab Revenue Market Share by Company in 2025
Figure 47. Global Toripalimab Sales Market Share by Geographic Region (2021-2026)
Figure 48. Global Toripalimab Revenue Market Share by Geographic Region in 2025
Figure 49. Americas Toripalimab Sales 2021-2026 (Units)
Figure 50. Americas Toripalimab Revenue 2021-2026 ($ millions)
Figure 51. APAC Toripalimab Sales 2021-2026 (Units)
Figure 52. APAC Toripalimab Revenue 2021-2026 ($ millions)
Figure 53. Europe Toripalimab Sales 2021-2026 (Units)
Figure 54. Europe Toripalimab Revenue 2021-2026 ($ millions)
Figure 55. Middle East & Africa Toripalimab Sales 2021-2026 (Units)
Figure 56. Middle East & Africa Toripalimab Revenue 2021-2026 ($ millions)
Figure 57. Americas Toripalimab Sales Market Share by Country in 2025
Figure 58. Americas Toripalimab Revenue Market Share by Country (2021-2026)
Figure 59. Americas Toripalimab Sales Market Share by Type (2021-2026)
Figure 60. Americas Toripalimab Sales Market Share by Application (2021-2026)
Figure 61. United States Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 62. Canada Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 63. Mexico Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 64. Brazil Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 65. APAC Toripalimab Sales Market Share by Region in 2025
Figure 66. APAC Toripalimab Revenue Market Share by Region (2021-2026)
Figure 67. APAC Toripalimab Sales Market Share by Type (2021-2026)
Figure 68. APAC Toripalimab Sales Market Share by Application (2021-2026)
Figure 69. China Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 70. Japan Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 71. South Korea Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 72. Southeast Asia Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 73. India Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 74. Australia Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 75. China Taiwan Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 76. Europe Toripalimab Sales Market Share by Country in 2025
Figure 77. Europe Toripalimab Revenue Market Share by Country (2021-2026)
Figure 78. Europe Toripalimab Sales Market Share by Type (2021-2026)
Figure 79. Europe Toripalimab Sales Market Share by Application (2021-2026)
Figure 80. Germany Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 81. France Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 82. UK Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 83. Italy Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 84. Russia Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 85. Middle East & Africa Toripalimab Sales Market Share by Country (2021-2026)
Figure 86. Middle East & Africa Toripalimab Sales Market Share by Type (2021-2026)
Figure 87. Middle East & Africa Toripalimab Sales Market Share by Application (2021-2026)
Figure 88. Egypt Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 89. South Africa Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 90. Israel Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 91. Turkey Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 92. GCC Countries Toripalimab Revenue Growth 2021-2026 ($ millions)
Figure 93. Manufacturing Cost Structure Analysis of Toripalimab in 2026
Figure 94. Manufacturing Process Analysis of Toripalimab
Figure 95. Industry Chain Structure of Toripalimab
Figure 96. Channels of Distribution
Figure 97. Global Toripalimab Sales Market Forecast by Region (2027-2032)
Figure 98. Global Toripalimab Revenue Market Share Forecast by Region (2027-2032)
Figure 99. Global Toripalimab Sales Market Share Forecast by Type (2027-2032)
Figure 100. Global Toripalimab Revenue Market Share Forecast by Type (2027-2032)
Figure 101. Global Toripalimab Sales Market Share Forecast by Application (2027-2032)
Figure 102. Global Toripalimab Revenue Market Share Forecast by Application (2027-2032)
